News 15 mai 2024 Allegria Therapeutics raises 3.5 million dollars in seed financing round Allegria Therapeutics has received seed funding of 3.5 million dollars from the founding investor Forty51 Ventures. The biotech startup is develo...
Aktuell 15 mai 2024 Allegria Therapeutics nimmt 3,5 Millionen Dollar in Seed-Runde ein Allegria Therapeutics hat eine Seed-Finanzierung von 3,5 Millionen Dollar durch den Gründungsinvestor Forty51 Ventures erhalten. Das Biotech-Star...
News 03 mai 2024 Basel research paves way for new drugs Chemists at the University of Basel have developed a new synthesis approach to artificially create terpenes. These contain substances that can be...
Success stories 23 abr 2024 How BeiGene drives global cancer treatment access From its European headquarters in Basel, Switzerland, BeiGene strategically collaborates with stakeholders worldwide to advance oncology research...
Exemples de Réussite 02 mai 2024 Comment BeiGene favorise l’accès au traitement du cancer à l’échelle mondiale Depuis son siège européen à Bâle, en Suisse, BeiGene collabore de manière stratégique avec des parties prenantes dans le monde entier pour f...
News 25 abr 2024 Swiss biotech achieves record revenues in 2023 Swiss biotech companies generated record revenues of 7.3 billion Swiss francs in 2023, while capital investments rose 50 per cent year on year to...
News 23 abr 2024 Swibrace advances to clinical phase with innovative 3D-printed wrist braces Swibrace, in partnership with the Inselspital in Bern, moves its customized wrist braces into clinical phase, enhancing fracture treatment throug...
News 10 abr 2024 Empa researchers develop cellulose-based aerogel A laboratory at the Swiss Federal Laboratories for Materials Science and Technology (Empa) has developed an ultralight, biodegradable and printab...
Actualités 23 abr 2024 Les orthèses de poignet innovantes imprimées en 3D de Swibrace passent à la phase clinique Swibrace, en partenariat avec l’Inselspital de Berne, fait passer ses attelles de poignet personnalisées en phase clinique, améliorant ainsi le t...
News 18 mar 2024 Neuria enters Vanguard Accelerator to gameify healthier lifestyles Neuria Digital Therapeutics has become the inaugural start-up of 2024 to be embraced by the Vanguard Accelerator program.
成功談 02 mai 2024 BeiGeneがグローバルながん治療へのアクセスをどのように推進しているか スイスのバーゼルにある欧州本部を拠点に、BeiGeneは世界中の関係者と 戦略的に協力し、腫瘍学の研究開発を推進しています。同社は、 40か国で商業活動を展開し、45か国以上で臨床試験を実施しています。 Sirpa ...
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
Actualités 18 mar 2024 Neuria intègre l’accélérateur Vanguard pour promouvoir des modes de vie plus sains Neuria Digital Therapeutics est la première start-up de 2024 à bénéficier du programme Vanguard Accelerator.
News 08 mai 2024 B. Braun Medical opens new factory in Sempach B. Braun Medical AG has commenced operations at a new production facility for disinfectant and hygiene products in Sempach. The company has inves...
News 10 mai 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...
News 07 mai 2024 UZH researching innovative cancer therapy Researchers from the University of Zurich (UZH) are in the process of developing new cancer therapeutics. Known as radiotheranostics, these drugs...
News 06 mai 2024 EY reports growth of 53 percent for investments in Switzerland Foreign investments in Europe fell by 4 percent in 2023. However, investments in Switzerland were up by 53 percent. These findings were reported ...
Market information 25 abr 2024 United Kingdom With a market of nearly 70 million inhabitants, the UK is the world’s fifth largest economy, with London contributing more than 20% of the countr...